Sonoma Pharmaceuticals, Inc. (SNOA, Financial) experienced a notable stock price increase of 5.02%, reaching $2.72 per share with a trading volume of 47,119 shares. The stock's turnover rate was recorded at 3.52% and showed a price fluctuation range of 7.34%. Recent financial data revealed that Sonoma Pharmaceuticals achieved a revenue of $3.39 million, a net loss of $1.14 million, and an earnings per share of -$1.34. The gross profit stood at $1.31 million, and the price-to-earnings ratio was -0.44. Among analysts, the single participating institution has unanimously rated the stock as a buy, with no hold or sell recommendations.
In the broader pharmaceutical sector, which saw an overall increase of 1.06%, other significant movers included Biofrontera Inc, Cyclo Therapeutics Inc, and Phibro Animal Health Corporation with notable gains. Meanwhile, stocks such as Biofrontera Inc. and Sunshine Biopharma Inc. saw high activity levels with turnover rates of 11.32%, 4.44%, and 4.02% respectively. Notably volatile stocks included Eton Pharmaceuticals, Inc. and Flora Growth Corp., showing fluctuations of 15.27% and 13.00% respectively.
Sonoma Pharmaceuticals is a specialty pharmaceutical company based in the United States, focusing on developing and commercializing differentiated therapies for chronic skin conditions. Their product lineup includes treatments such as Celacyn, Ceramax, Mondoxyne, SebuDerm, and others, targeting skin issues like acne, atopic dermatitis, and scars. Sonoma's revenue is generated from product sales across the U.S., Latin America, Europe, Asia, and other regions.
